Mike Hanna

Mike Hanna

My group has a long standing clinical and genetic research interest in neurological channelopathies and in mitochondrial neuromuscular diseases. We are also interested in mechanisms of muscle degeneration in acquired muscle disease particularly IBM.

Continuing to develop natural history studies and new clinical trials in these neuromuscular disease groups will be an important focus of the MRC centre.

We are part of the North American muscle study group.

Research

Human Neuromuscular Channelopathies

We undertake clinical and genetic research in human muscle ion channelopathies including periodic paralysis and all myotonic disorders. Over the last ten years we have established one of the largest clinic-genetic databases in the world of human patients with genetic channelopathies affecting skeletal muscle. We provide a national specialist clinical service for patients with muscle channelopathies supported by the DoH National Commissioning Group [NCG]. We are currently undertaking NIH funded natural history studies in muscle channelopathies [non-dystrophic myotonias and periodic paralysis]. In addition we are commencing an NIH funded multicentre treatment trial in periodic paralysis, and Professor Hanna is on the advisory Panel for Periodic Paralysis International http://hkpp.org. We are part of the Rare Diseases Research Network and the NIH CINCH consortium for clinical trials in human channelopathies http://rarediseasesnetwork.epi.usf.edu/cinch/

Chloride channel

Linked to our clinical work we also undertake genetic and molecular work to elucidate the pathogenesis of muscle damage in muscle channelopathies in collaboration with other members of the MRC Centre, Dimitri Kullmann and Stephanie Schorge. We have defined the molecular genetic basis of many muscle channelopathy cohorts and we evaluate the effects on channel function through a range of expression systems. We are part of the Oxford ion channel consortium http://oxion.dpag.ox.ac.uk/ Funding: DoH [NSCG], MRC, NIH [USA] and Action Research.

Please click here to read more about Ion Channel Research.

Human mitochondrial diseases

RRF

We undertake clinical and genetic research in our large cohort of mitochondrial disease patients. Through a consortium with Newcastle and Oxford funded by NCG we provide a national clinical and diagnostic service for patients with complex mitochondrial diseases. Over the last 15 years we have defined many primary defects in mtDNA associated with human disease. We are interested in elucidating the molecular pathogenesis of mtDNA associated disease using various cellular expression systems and human primary myoblasts and in developing therapeutic interventions in vitro and in vivo. We collaborate closely with other MRC Centre PIs Michael Duchen, Doug Turnbull, Patrick Chinnery and with Shamima Rahman Funding: DoH [NSCG], MRC.

Mechanisms of muscle degeneration in IBM

DRG

We are undertaking clinical and genetic studies and we are adopting a novel treatment trial approach in Inclusion Body Myopathy. IBM is the commonest serious acquired muscle wasting disease over age 40y and is of unknown cause and has no treatment. In collaboration with MRC Centre PI’s Linda Greensmith and John Hardy we are investigating genetic risk factors for IBM and evaluating muscle degeneration in an IBM animal model.

Channelopathies

We undertake clinical and genetic research in human muscle ion channelopathies including periodic paralysis and all myotonic disorders. Over the last ten years we have established one of the largest clinic-genetic databases in the world of human patients with genetic channelopathies affecting skeletal muscle. We provide a national specialist clinical service for patients with muscle channelopathies supported by the DoH National Commissioning Group [NCG].

We are currently undertaking NIH funded natural history studies in muscle channelopathies [non-dystrophic myotonias and periodic paralysis]. In addition we are commencing an NIH funded multicentre treatment trial in periodic paralysis. We are part of the Rare Diseases Research Network and the NIH CINCH consortium for clinical trials in human channelopathies http://rarediseasesnetwork.epi.usf.edu/cinch/

Linked to our clinical work we also undertake genetic and molecular work to elucidate the pathogenesis of muscle damage in muscle channelopathies in collaboration with other members of the MRC Centre, Dimitri Kullmann and Stephanie Schorge. We have defined the molecular genetic basis of many muscle channelopathy cohorts and we evaluate the effects on channel function through a range of expression systems. We are part of the Oxford ion channel consortium http://oxion.dpag.ox.ac.uk/ Funding: DoH [NSCG], MRC, NIH [USA] and Action Research.

Please click here to read more about Ion Channel Research.

Please click here to view the 2014 Research Excellence Framework Channelopathies Impact Case study.

Contact

Publications

View a list of Mike's Publications

Contact details

Professor Michael G. Hanna

UCL Institute of Neurology
Box 102
The National Hospital for Neurology and Neurosurgery
Queen Square
London WC1N 3BG


Phone: +44 (0)203 448 8014
E-mail: m.hanna@ucl.ac.uk